Critics Suggest FDA Approving Aduhelm Will Erode the “Public Trust”: What About Patients’ Trust?
FDA Law
JUNE 23, 2021
Janet Woodcock’s leadership, identified the need for more systematic patient engagement — a way to improve representativeness and be more proactive rather than reactive to interacting with patient communities. 25, 2014). So, we crafted the Patient-Focused Drug Development, or PFDD, a commitment that was agreed to in PDUFA V.
52 
Let's personalize your content